Libtayo Libtayo

Libtayo Libtayo

Generic name: Cemiplimab-rwlc

Commercial name: Libtayo

Company: Regeneron 

FDA approval date: 09/28/2018

NMPA approval date: not yet approved


Indications and usage

for the treatment of metastatic cutaneous squamous cell carcinoma


Dosage Form/Route:

350 mg as an intravenous infusion over 30 minutes every 3 weeks.


Mechanism of Action

a type of immunotherapy treatment called a programmed death receptor-1 (PD-1) inhibitor


Adverse Reactions

The most common side effects of Libtayo include fatigue, rash and diarrhea

其他药品

预约跨境治疗服务
请留下您的联系方式,我们将第一时间与你取得联系
选择预约类型
Phone全国服务热线 400-076-3808
爱医传递